US biopharmaceutical firm Cephalon has filed a supplemental New Drug Application with the Food and Drug Administration, seeking clearance to market Fentora (fentanyl buccal tablet) for the management of breakthrough pain in opioid resistant patients. The drug was approved last year for the treatment of breakthrough cancer pain (Marketletter October 2, 2006).
Cephalon said that the sNDA includes data from three, randomized placebo-controlled trials and one long-term safety assessment. Participants with a range of chronic conditions, including lower back and neuropathic pain, were treated for up to 18 months. The results showed that opioid tolerant patients who received treatment achieved significant improvements in terms of both relief from breakthrough pain and the duration of this effect.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze